Evidence map›Paper›PMID 35574408›Full record

SynthesisFrontiers in oncology2022

Extra-Neural Metastases From Primary Intracranial Ependymomas: A Systematic Review.

Paolo Palmisciano, Gianluca Ferini, Fabio Barone, Vishal Chavda, Fabrizio Romano, Paolo Amico, Donatella Emmanuele, Giovanni F Nicoletti, Gianluca Pompili, Giuseppe Roberto Giammalva and 7 more

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Paolo PalmiscianoDepartment of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, Catania, Italy.
Gianluca FeriniDepartment of Radiation Oncology, REM Radioterapia srl, Viagrande, Italy.
Fabio BaroneDepartment of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, Catania, Italy.
Vishal ChavdaDepartment of Pathology, Stanford School of Medicine, Stanford University Medical Center, Palo Alto, CA, United States.
Fabrizio RomanoMedical Oncology Unit, Umberto I Hospital, Siracusa, Italy.
Paolo AmicoDepartment of Pathological Anatomy, Cannizzaro Hospital, Catania, Italy.
Donatella EmmanueleDepartment of Pathological Anatomy, Cannizzaro Hospital, Catania, Italy.
Giovanni F NicolettiDepartment of Neurosurgery, Highly Specialized Hospital of National Importance "Garibaldi", Catania, Italy.
Gianluca PompiliPlastic Surgery Unit, Cannizzaro Hospital, Catania, Italy.
Giuseppe Roberto GiammalvaUnit of Neurosurgery, Department of Biomedical Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy.
Rosario MaugeriUnit of Neurosurgery, Department of Biomedical Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy.
Domenico Gerardo IacopinoUnit of Neurosurgery, Department of Biomedical Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy.
Lidia StrigariDepartment of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Tseng T YeoDepartment of Surgery, Division of Neurosurgery, National University Hospital, Singapore, Singapore.
Salvatore CiceroDepartment of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, Catania, Italy.
Gianluca ScaliaDepartment of Neurosurgery, Highly Specialized Hospital of National Importance "Garibaldi", Catania, Italy.
Giuseppe Emmanuele UmanaDepartment of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, Catania, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary intracranial ependymomas (IE) are rare brain tumors rarely metastasizing outside the central nervous system. We systematically reviewed the literature on extra-neural metastases from primary IEs. Methods: PubMed, Scopus, Web-of-Science, and Cochrane were searched following the PRISMA guidelines to include studies of extra-neural metastases from primary IEs. Clinical features, management strategies, and survival were analyzed. Results: We collected 48 patients from 43 studies. Median age was 13 years (range, 2-65). Primary IEs were frequently located in the parietal (22.9%) and frontal (16.7%) lobes, and mostly treated with resection (95.8%) and/or radiotherapy (62.5%). Most IEs were of grade-III (79.1%), and few of grade-I (6.3%) or grade-II (14.6%). 45 patients experienced intracranial recurrences, mostly treated with resection (86.7%), radiotherapy (60%), and/or chemotherapy (24.4%). Median time-interval from primary IEs was 28 months (range, 0-140). Most extra-neural metastases were diagnosed at imaging (37.5%) or autopsy (35.4%). Extra-neural metastases were multifocal in 38 patients (79.1%), mostly involving cervical or hilar lymph-nodes (66.7%), lung/pleura (47.9%), and/or scalp (29.1%). Surgical resection (31.3%), chemotherapy (31.3%) and locoregional radiotherapy (18.8%) were the most common treatments for extra-neural metastases, but 28 (58.3%) patients were not treated. At last follow-up, 37 patients died with median overall-survivals from primary IEs of 36 months (range, 1-239), and from extra-neural metastases of 3 months (range, 0.1-36). Overall-survival was significantly longer in patients with grade-I and II IEs (P=0.040). Conclusion: Extra-neural metastases from primary IEs are rare, but mostly occur at later disease stages. Multidisciplinary management strategies should be intended mostly for palliation.

Indexed as

ependymomaextra-neural metastasesneuro-oncologyscalp metastasessystematic review

Identifiers

PMID35574408
PMCPMC9093681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.